Vaxil announces key US Patent and Trademark Office Notice of Allowance for its immunotherapy
First US Patent issued to Vaxil since the company began developing its immunotherapies 10 years ago.
Vaxil Bio has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for a patent providing broad coverage over Vaxil's immunotherapy platform and its lead product, Orphan Drug Designated Immucin.
This will become the first US Patent issued to Vaxil since the company began developing its immunotherapies 10 years ago. ImMucin is an immunotherapy intended to train a patient's immune system, particularly T-cells and antibodies, to attack cancer cells via a specific domain, called the signal peptide, of the tumour marker MUC1. This domain bears significant advantages as an immunotherapeutic modality including its presence on approximately 90% of all cancer types. The notice indicates the patentability of claims covering the ImMucin peptide as well as claims reciting methods for treating or inhibiting cancer using the ImMucin peptide. This is a highly important addition to Vaxil's existing patent portfolio and strengthens the company's ability to protect its proprietary technologies as it continues rigorous testing and advancement of ImMucin. Moreover, it positions Vaxil as the only player able to use the 21-mer peptide known as ImMucin for all MUC1 positive tumours. Immucin is the first product generated from Vaxil's proprietary VaxHit platform, and has been awarded Orphan Drug Status from the FDA and EMA. Vaxil believes there is potential for VaxHit to generate additional immunotherapy products targeting the signal peptide domains of other prominent tumour markers.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance